Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

NCT06719024
completedphase_4

Menthol for PDT Pain Relief

NCT02984072
completedphase_3

Intradermal Influenza Vaccine in the Young

NCT02103023
completednot_applicable

Intradermal Trivalent Influenza Vaccine With Imiquimod

NCT01508884

Clinical Trials (4)

Showing 4 of 4 trials
NCT06719024Phase 2

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

Recruiting
NCT02984072Phase 4

Menthol for PDT Pain Relief

Completed
NCT02103023Phase 3

Intradermal Influenza Vaccine in the Young

Completed
NCT01508884Not Applicable

Intradermal Trivalent Influenza Vaccine With Imiquimod

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4